FORM 4

Check this box if no longer subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response	. 0.5									

to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b).

	nd Address of n Cyrus	Reporting Person*									ng Symbol <u>Inc.</u> [OL	MA]			c all appl	tor	0	10%	Owner		
(Last) (First) (Middle) C/O OLEMA PHARMACEUTICALS, INC. 512 2ND STREET, 4TH FLOOR						3. Date of Earliest Transaction (Month/Day/Year) 07/20/2021									X Officer (give title Other (specify below) CHIEF TECHNOLOGY OFFICER						
(Street) SAN FRANCISCO CA 94107					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(St		Zip)	lon-Deriva	ative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye				n (ear)	2A. Deemed Execution Date,		, 3 T	3. Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
								G		v	Amount	(A) or (D)	Price	Transacti (Instr. 3 a		ion(s)			(Instr. 4)		
Common Stock 07/19/202				.1			S ⁽¹⁾		7,877	D	\$24.83	(2)	1,091	1,669		D					
Common	Stock			07/20/20	21				S ⁽¹⁾		4,123	D	\$25.63	(3)	1,087,546		D				
Common	Stock														122,028				See Footnote ⁽⁴⁾		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exec if an	Deemed cution Date, y nth/Day/Year)		action (Instr.	5. Nur of Deriva Secur Acqui (A) or Dispo of (D) (Instr. and 5)	ative ities red sed 3, 4	Expi	iration	ercisable and Date y/Year)	Amou Secu Unde Deriv	rities rlying ative rity (Instr.	Der Sec (Ins	Price of ivative curity str. 5)	9. Numbo derivativ Securitie Beneficia Owned Followin Reported Transact (Instr. 4)	re Owners es Form: ally Direct (i) or Indirect d (i) (Insti		Beneficial Ownership ot (Instr. 4)		
						v	(A)	(D)	Date Exercisable		Expiration e Date	Title	Amount or Number of Shares								

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- 2. The weighted average sale price for the transaction reported was \$24.83, and the range of prices were between \$24.75 and \$24.95. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- 3. The weighted average sale price for the transaction reported was \$25.63, and the range of prices were between \$25.14 and \$26.10. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- 4. The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.

/s/ John B. Moriarty, Jr., 07/21/2021 Attorney-in-Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.